Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lutetium Lu 177 Zadavotide Guraxetan

Radiopharmaceutical · Kills target cells, directed at prostate-specific membrane antigen (FOLH1) · developed by Lantheus Medical Imaging

Phase 1/2 Most advanced trial (none active)
LNTH Developer
2 Registered trials

What is Lutetium Lu 177 Zadavotide Guraxetan?

Lutetium Lu 177 zadavotide guraxetan is a radioconjugate in which a PSMA-targeting ligand is linked to the beta-emitting radioisotope lutetium-177. The ligand binds prostate-specific membrane antigen on tumor cells, delivering beta radiation that destroys them. It is studied in castration-resistant prostate cancer and metastatic renal cell carcinoma, including in combination with pembrolizumab.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
177Lu-PNT2002, [Lu-177]-PNT2002
Drug type
Radiopharmaceutical
Targets
prostate-specific membrane antigen (FOLH1)
Mechanism
Kills target cells, directed at prostate-specific membrane antigen (FOLH1)
Therapy area
Oncology
Developer
Lantheus Medical Imaging (LNTH)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
G5B860B0G1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06361810 Phase 1/2 Metastatic Renal Cell Carcinoma Withdrawn LNTH
NCT06033001 N/A Castration-Resistant Prostatic Cancer Temporarily not available LNTH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Castration-Resistant Prostatic CancerMetastatic Clear Cell Renal Cell CarcinomaMetastatic Renal Cell Carcinoma

Other drugs acting on FOLH1

More from Lantheus Medical Imaging

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LNTH page.

Follow LNTH, the company behind Lutetium Lu 177 Zadavotide Guraxetan

See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LNTH catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.